Iatrogenic Creutzfeldt-Jakob disease, final assessment.
Iatrogenic Creutzfeldt-Jakob disease, final assessment.
复制标题
DOI:
10.3201/eid1806.120116
复制
发表时间:
2012-06
影响因子:
11.8
通讯作者:
Schonberger LB
中科院分区:
文献类型:
--
作者:
Brown P;Brandel JP;Sato T;Nakamura Y;MacKenzie J;Will RG;Ladogana A;Pocchiari M;Leschek EW;Schonberger LB
The book on iatrogenic Creutzfeldt-Jakob disease (CJD) in humans is almost closed. This form of CJD transmission via medical misadventures was first detected in 1974. Today, only occasional CJD cases with exceptionally long incubation periods still appear. The main sources of the largest outbreaks were tissues from human cadavers with unsuspected CJD that were used for dura mater grafts and growth hormone extracts. A few additional cases resulted from neurosurgical instrument contamination, corneal grafts, gonadotrophic hormone, and secondary infections from blood transfusions. Although the final solution to the problem of iatrogenic CJD is still not available (a laboratory test to identify potential donors who harbor the infectious agent), certain other measures have worked well: applying special sterilization of penetrating surgical instruments, reducing the infectious potential of donor blood and tissue, and excluding donors known to have higher than normal risk for CJD. The era of iatrogenic Creutzfeldt-Jakob disease (CJD) has nearly closed; only occasional cases with exceptionally long incubation periods are still appearing. The principal sources of these outbreaks are contaminated growth hormone (226 cases) and dura mater grafts (228 cases) derived from human cadavers with undiagnosed CJD infections; a small number of additional cases are caused by neurosurgical instrument contamination, corneal grafts, gonadotrophic hormone, and secondary infection with variant CJD transmitted by transfusion of blood products. No new sources of disease have been identified, and current practices, which combine improved recognition of potentially infected persons with new disinfection methods for fragile surgical instruments and biological products, should continue to minimize the risk for iatrogenic disease until a blood screening test for the detection of preclinical infection is validated for human use.
登录
查看更多内容
影响因子:
6.4
作者:
Orrú CD;Wilham JM;Raymond LD;Kuhn F;Schroeder B;Raeber AJ;Caughey B
通讯作者:
Caughey B
DOI:
10.1186/1476-069x-7-31
发表时间:
2008-06-24
期刊:
Environmental health : a global access science source
影响因子:
--
作者:
Garruto RM;Reiber C;Alfonso MP;Gastrich H;Needham K;Sunderman S;Walker S;Weeks J;Derosa N;Faisst E;Dunn J;Fanelli K;Shilkret K
通讯作者:
Shilkret K
影响因子:
168.9
作者:
Gregori, Luisa;Gurgel, Patrick V.;Rohwer, Robert G.
通讯作者:
Rohwer, Robert G.
影响因子:
2.3
作者:
Yamada, Masahito;Noguchi-Shinohara, Moeko;Mizusawa, Hidehiro
通讯作者:
Mizusawa, Hidehiro
影响因子:
9.9
作者:
Ladogana, A;Puopolo, M;Zerr, I
通讯作者:
Zerr, I